Torrent Pharma Inc Importer EIN 36-4547412

Torrent Pharma Inc., identified by Importer EIN 36-4547412, is a pharmaceutical importer based in the United States. The company operates as a buyer, sourcing finished pharmaceutical formulations from international suppliers for distribution within the U.S. market. Headquartered at 150 Allen Road, Basking Ridge, NJ 07920, Torrent Pharma Inc. is a subsidiary of Torrent Pharmaceuticals Limited, a leading Indian pharmaceutical company. Torrent Pharmaceuticals Limited is renowned for its extensive portfolio in therapeutic areas such as cardiovascular, central nervous system, gastro-intestinal, and women's healthcare.

In the United States, Torrent Pharma Inc. plays a pivotal role in the pharmaceutical distribution network by importing and supplying a range of finished drug products. These products are intended for various segments of the U.S. healthcare system, including retail pharmacies, hospitals, and clinics. The company's operations are integral to ensuring the availability of essential medications sourced from international markets, thereby contributing to the diversity and competitiveness of the U.S. pharmaceutical supply chain.

Torrent Pharma Inc. maintains a centralized distribution facility at its headquarters in Basking Ridge, New Jersey. This strategic location provides efficient access to major transportation hubs, facilitating the timely importation and distribution of pharmaceutical products. The company's logistics capabilities are designed to manage a diverse product portfolio, ensuring compliance with U.S. regulatory standards and meeting the demands of various healthcare providers across the country.

While specific details regarding additional warehouse locations or distribution centers are not publicly disclosed, Torrent Pharma Inc.'s operations are structured to support nationwide distribution. The company's logistics infrastructure is equipped to handle the complexities of importing finished pharmaceutical formulations, including adherence to FDA regulations and quality control measures. This setup enables Torrent Pharma Inc. to effectively serve the U.S. market, ensuring that imported medications are accessible to healthcare providers and patients nationwide.

Torrent Pharma Inc. functions primarily as a pharmaceutical importer and distributor within the United States. By sourcing finished pharmaceutical formulations from international suppliers, particularly from its parent company, Torrent Pharmaceuticals Limited, it plays a crucial role in enhancing the diversity and competitiveness of the U.S. pharmaceutical market. The company's activities support the availability of a wide range of medications, contributing to the overall efficiency and resilience of the U.S. healthcare system.

In the U.S. pharmaceutical supply chain, Torrent Pharma Inc. serves as an intermediary between foreign manufacturers and domestic healthcare providers. Its operations ensure that imported pharmaceutical products meet the stringent standards set by U.S. regulatory bodies, including the FDA. By maintaining compliance with these regulations, Torrent Pharma Inc. upholds the integrity of the U.S. drug supply, ensuring that imported medications are safe, effective, and of high quality.

Torrent Pharma Inc. demonstrates a high degree of sourcing concentration, with all its pharmaceutical imports originating from a single supplier: Torrent Pharmaceuticals Limited. This exclusive sourcing strategy results in a total import value of $3.3 million USD across 66 shipments, encompassing 27 unique formulations. The top three imported products—Citalopram, Escitalopram, and Minocycline—account for the majority of the import value, indicating a focused product portfolio.

The reliance on a single supplier can present both strategic advantages and potential risks. On the positive side, this concentration may lead to streamlined operations, simplified logistics, and potentially favorable terms due to the volume of business with Torrent Pharmaceuticals Limited. However, such dependency also exposes Torrent Pharma Inc. to risks associated with supply chain disruptions, regulatory changes affecting the supplier, or any operational challenges faced by Torrent Pharmaceuticals Limited. To mitigate these risks, it would be prudent for Torrent Pharma Inc. to consider diversifying its supplier base and exploring alternative sources for its pharmaceutical imports.

The shipment data reveals a consistent pattern of imports from Torrent Pharmaceuticals Limited, suggesting a stable and ongoing relationship. This stability is crucial for maintaining a reliable supply of pharmaceutical products to the U.S. market. Nonetheless, the absence of alternative suppliers underscores the importance of proactive risk management strategies to ensure continuity of supply and to safeguard against potential disruptions in the supply chain.

Torrent Pharma Inc.'s supply chain resilience is closely tied to the operations of its sole supplier, Torrent Pharmaceuticals Limited. The company's importation of finished pharmaceutical formulations from India necessitates a robust and compliant supply chain to meet U.S. regulatory standards. The FDA requires that all foreign drug establishments whose products are imported into the United States register their establishments and list all their drug products in commercial distribution in the U.S.

Given the exclusive sourcing arrangement, Torrent Pharma Inc. may face challenges in ensuring supply chain continuity in the event of disruptions affecting Torrent Pharmaceuticals Limited. To enhance resilience, it would be beneficial for Torrent Pharma Inc. to establish relationships with additional suppliers and diversify its product formulations. This approach would provide alternative sources and formulations, reducing dependency on a single supplier and mitigating potential risks associated with supply chain disruptions.

Furthermore, ensuring that all suppliers comply with Good Manufacturing Practice (GMP) standards is essential for maintaining product quality and regulatory compliance. The FDA enforces strict regulations on imported drugs, and products that do not meet these standards may be refused entry into the U.S. market.

Torrent Pharma Inc.'s sourcing pattern, characterized by exclusive reliance on Torrent Pharmaceuticals Limited, has significant strategic implications. While this focused approach may offer operational efficiencies and potentially favorable terms, it also exposes the company to risks associated with supply chain disruptions, regulatory changes, and operational challenges within the supplier's operations.

For Torrent Pharma Inc., diversifying its supplier base could enhance supply chain resilience and reduce dependency on a single source. Engaging with multiple suppliers would provide alternative sources for pharmaceutical products, mitigating risks associated with potential disruptions in the supply chain. Additionally, expanding the range of imported formulations could cater to a broader spectrum of therapeutic areas, aligning with market demands and enhancing the company's competitive position in the U.S. pharmaceutical market.

For Indian exporters seeking to become alternative suppliers to Torrent Pharma Inc., understanding the company's current sourcing strategy is crucial. Demonstrating compliance with FDA regulations, including GMP standards, and offering a diverse portfolio of high-quality pharmaceutical formulations could position these exporters as viable alternatives. Building relationships with Torrent Pharma Inc. would require a clear understanding of the company's operational requirements and a commitment to meeting the stringent standards expected in the U.S. market.

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation of pharmaceutical products. The FDA enforces the Federal Food, Drug, and Cosmetic Act (FD&C Act), which governs the importation, manufacturing, and distribution of drugs within the U.S. This legislation ensures that all drugs, including those imported from foreign countries, meet the necessary standards for safety, efficacy, and quality.

The FDA's regulatory framework for pharmaceutical imports includes several key components:

• Registration and Listing: Foreign drug establishments must register with the FDA and list all their drug products intended for import into the U.S. market. This process ensures that the FDA is aware of all drugs entering the country and can monitor their compliance with U.S. regulations.

• Import Procedures: Importers are required to file an entry notice and an entry bond with U.S. Customs and Border Protection (CBP) when offering a drug for import. The FDA reviews these entries to determine the admissibility of the products, ensuring they meet all regulatory requirements.

• Compliance and Enforcement: The FDA conducts inspections and examinations of imported drugs to verify compliance with the FD&C Act. Products that do not meet FDA standards may be refused entry into the U.S. market.

Understanding this regulatory framework is essential for companies like Torrent Pharma Inc. to ensure that their imported pharmaceutical products are compliant with U.S. laws and regulations, thereby maintaining the integrity and safety of the U.S. drug supply.

Import licensing requirements for pharmaceutical products entering the United States are governed by the FDA. All foreign drug establishments whose products are imported into the U.S. must register with the FDA and list all their drug products intended for commercial distribution in the U.S. market.

In addition to registration, imported pharmaceutical products must comply with Good Manufacturing Practice (GMP) standards. The FDA requires that all drugs, including those imported from foreign countries, meet GMP standards to ensure their safety, efficacy, and quality. Manufacturers must provide evidence of GMP compliance, which may include certifications such as EU GMP, WHO GMP, or PIC/S.

Importers like Torrent Pharma Inc. are responsible for ensuring that their imported products meet these licensing and